Novel therapies for Hodgkin lymphoma

John W. Sweetenham

doi:10.1177/2040620710387980

Novel therapies for Hodgkin lymphoma

John W. Sweetenham

Research output: Contribution to journal › Article › peer-review

Abstract

In recent years, improved understanding of the biology of Hodgkin lymphoma (HL) has uncovered many potential targets for the treatment of this disease. Clarification of the B-cell origin of the Hodgkin Reed Sternberg (HRS) cell and of the complex interactions between the HRS cell and the HL microenvironment have provided new insights into the pathophysiology of HL and identified extracellular and intracellular molecules which are essential for HRS survival. New agents directed at these molecules are now in early phase clinical trials.

Original language	English (US)
Pages (from-to)	23-29
Number of pages	7
Journal	Therapeutic Advances in Hematology
Volume	1
Issue number	1
DOIs	https://doi.org/10.1177/2040620710387980
State	Published - Dec 2010
Externally published	Yes

Keywords

Hodgkin lymphoma
new agents
targeted therapy

ASJC Scopus subject areas

Hematology

Access to Document

10.1177/2040620710387980

Cite this

@article{60353664da994a29ad7ff6f003164d27,

title = "Novel therapies for Hodgkin lymphoma",

abstract = "In recent years, improved understanding of the biology of Hodgkin lymphoma (HL) has uncovered many potential targets for the treatment of this disease. Clarification of the B-cell origin of the Hodgkin Reed Sternberg (HRS) cell and of the complex interactions between the HRS cell and the HL microenvironment have provided new insights into the pathophysiology of HL and identified extracellular and intracellular molecules which are essential for HRS survival. New agents directed at these molecules are now in early phase clinical trials.",

keywords = "Hodgkin lymphoma, new agents, targeted therapy",

author = "Sweetenham, {John W.}",

year = "2010",

month = dec,

doi = "10.1177/2040620710387980",

language = "English (US)",

volume = "1",

pages = "23--29",

journal = "Therapeutic Advances in Hematology",

issn = "2040-6207",

publisher = "Sage Publications",

number = "1",

}

TY - JOUR

T1 - Novel therapies for Hodgkin lymphoma

AU - Sweetenham, John W.

PY - 2010/12

Y1 - 2010/12

N2 - In recent years, improved understanding of the biology of Hodgkin lymphoma (HL) has uncovered many potential targets for the treatment of this disease. Clarification of the B-cell origin of the Hodgkin Reed Sternberg (HRS) cell and of the complex interactions between the HRS cell and the HL microenvironment have provided new insights into the pathophysiology of HL and identified extracellular and intracellular molecules which are essential for HRS survival. New agents directed at these molecules are now in early phase clinical trials.

AB - In recent years, improved understanding of the biology of Hodgkin lymphoma (HL) has uncovered many potential targets for the treatment of this disease. Clarification of the B-cell origin of the Hodgkin Reed Sternberg (HRS) cell and of the complex interactions between the HRS cell and the HL microenvironment have provided new insights into the pathophysiology of HL and identified extracellular and intracellular molecules which are essential for HRS survival. New agents directed at these molecules are now in early phase clinical trials.

KW - Hodgkin lymphoma

KW - new agents

KW - targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=84993682617&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84993682617&partnerID=8YFLogxK

U2 - 10.1177/2040620710387980

DO - 10.1177/2040620710387980

M3 - Article

C2 - 23556069

AN - SCOPUS:84993682617

SN - 2040-6207

VL - 1

SP - 23

EP - 29

JO - Therapeutic Advances in Hematology

JF - Therapeutic Advances in Hematology

IS - 1

ER -

Novel therapies for Hodgkin lymphoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this